Molecular Health GmbH announced today that it has entered into an agreement to provide genetic analysis services using MH Guide/BRCA and
MH Guide/Mendel.
Molecular Health and CENTOGENE announced today that they will collaborate to initiate the Real-life data and Innovative Bioinformatic Algorithms (RIBA) project – starting with Epilepsy as the first indication.
BRCA1/2 variants are prognostic biomarkers for hereditary breast and/or ovarian cancer (HBOC) syndrome and predictive biomarkers for PARP inhibition.
Klicken Sie auf den unteren Button, um den Inhalt von www.linkedin.com zu laden.
Over the last decade, Dataome has grown to become one of the largest globally available resources of clinico-molecular data and knowledge. From millions of patient lives to hundreds of billions of molecular data points, it provides a single-point of access to the worlds biomedical knowledge through our decision support applications.
Molecular Health Predict (MH Predict) is an application to predict clinical trials probabilities of success. It enables the improvement of clinical trial success and reduces clinical trial failure while optimizing resource allocation for the biopharma industry and investors and enhancing the overall efficiency of drug development.
Molecular Health Guide Mendel (MH Mendel) supports human geneticists to identify clinically significant genetic variants and create a diagnostic report for individual patients. MH Mendel is part of the Molecular Health Guide (MH Guide) solution which is an IVD registered in the EU.
Molecular Health Guide (MH Guide) identifies safe and effective therapies for patients by analyzing the molecular profile. It matches detected mutations to the world’s knowledge in the field of oncology and hereditary diseases and helps medical experts to create a patient-specific clinical report. MH Guide is an IVD registered in the EU.
Molecular Health Guide BRCA (MH BRCA) supports medical professionals in identifying and reporting clinically significant germline variants associated with hereditary breast and ovarian cancer (HBOC) syndrome from NGS-based assessment of BRCA1 and BRCA2 and other HBOC related genes. MH BRCA is part of the Molecular Health Guide (MH Guide) solution which is an IVD registered in the EU.
Molecular Health’s growing number of customers and partnerships include some of the best hospitals, laboratories, universities, and genetic facilities in the world.
To find out more, you can call our customer care team or send us an e-mail. We would be delighted to provide you with more information or answer your questions.
